2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery

Front

1 of 3 · Front

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery

2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery

In one breath

The 2022 ASMBS/IFSO indications statement (Domain 09 filing of the same guideline as the Domain 02 record): metabolic and bariatric surgery recommended at BMI above 35 kg/m², to be considered at BMI 30–34.9 kg/m² with metabolic disease, with adjusted Asian thresholds.

Edition2022

Issued byAmerican Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)

Place of issueInternational

PublishedObesity Surgery · 2023;33(1):3–14

⏳ Pending verification

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 1

2 of 3 · Back 1

Back colours mark the reading sections — the chapter colour is the band and chip.

§1 · What it covers

This guideline covers adult candidates for MBS, with sections also addressing adolescents, older adults, BMI, diabetes, procedure choice, safety, and long-term outcomes. The key adult recommendations are: MBS is recommended for BMI >35 kg/m² regardless of presence, absence, or severity of comorbidities; MBS should be considered for BMI 30–34.9 kg/m² when metabolic disease is present and/or durable weight-loss or comorbidity improvement has not been achieved with nonsurgical methods; Asian BMI thresholds should be adjusted so BMI >25 kg/m² suggests clinical obesity and BMI >27.5 kg/m² should prompt offering MBS; appropriately selected adolescents may be considered. The statement supports sleeve gastrectomy and RYGB as dominant contemporary procedures, minimally invasive approaches, multidisciplinary evaluation, informed consent, and lifelong medical surveillance.

Applies to: Population as stated in report; verify full source.

§2 · Key recommendations

adult candidates for MBS, with sections also addressing adolescents, older adults, BMI, diabetes, procedure choice, safety, and long-term outcomes.
The key adult recommendations are: MBS is recommended for BMI >35 kg/m² regardless of presence, absence, or severity of comorbidities.
MBS should be considered for BMI 30–34.9 kg/m² when metabolic disease is present and/or durable weight-loss or comorbidity improvement has not been achieved with nonsurgical methods.
Asian BMI thresholds should be adjusted so BMI >25 kg/m² suggests clinical obesity and BMI >27.5 kg/m² should prompt offering MBS.
appropriately selected adolescents may be considered.
The statement supports sleeve gastrectomy and RYGB as dominant contemporary procedures, minimally invasive approaches, multidisciplinary evaluation, informed consent, and lifelong medical surveillance.

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

Back 2

3 of 3 · Back 2

Back colours mark the reading sections — the chapter colour is the band and chip.

§3 · Evidence & grading

the 2022 article is an evidence-informed society guideline but does not present a single GRADE strength-of-recommendation table for every recommendation. It synthesizes RCTs, cohort studies, systematic reviews, and expert global practice. Perioperative mortality is described as very low (approximately 0.03–0.2% in the cited literature), but the document is not a procedure-specific complication-management manual.

§4 · What changed in this edition

Not yet established — pending verification.

§5 · Source & working link

Eisenberg D, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg. 2023;33(1):3–14. doi:10.1007/s11695-022-06332-1 · PMID 36336720.

DOI — 10.1007/s11695-022-06332-1 ↗PubMed — PMID 36336720 ↗

Link check 2026-11-11: the record carries no original_url. The DOI and PubMed record (PMID 36336720) printed in the record's own text were fetched live — title, journal, volume and pages match; the canonical society resource is Not yet established — pending verification, so no Publisher row is printed.

Source: Tamer-supplied guideline index, intake 2026-11-10 (record #93, Domain 09) · Card built 2026-11-11 (Wave D) from the record itself; the §5.2 verification pass (UpToDate + Medscape → Perplexity → Tamer decision) has not yet run on this card. Completed in verification: title / issuedBy — The record's own key_recommendation text ('Exact title … Issuing societies …'), cross-verified at Crossref/PubMed for DOI 10.1007/s11695-022-06332-1, live 2026-11-11. ⚑ Conflict flag on the source record — documented cross-society disagreement (intake DOCX Table 2): Bariatric eligibility — ASMBS/IFSO 2022 vs NICE NG246 2025/2026. Unresolved — pending the verification pass (UpToDate + Medscape → Perplexity → Tamer decision).

FACE COLOURS Front — the summary · Back 1 — what it covers + key recommendations · Back 2 — evidence, changes + source

gl-div11-asmbs-ifso-indications-2022GS.code · Guidelines

More in Division 11 · Bariatric & Metabolic Surgery

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery⏳ Pending verification

2022 ASMBS and IFSO Indications for Metabolic and Bariatric Surgery

The 2022 ASMBS/IFSO indications for metabolic and bariatric surgery: recommended at BMI above 35 kg/m² regardless of comorbidity, to be considered at BMI 30–34.9 kg/m² with metabolic disease, with lower thresholds for Asian populations.

2022 · American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery⏳ Pending verification

Scientific Evidence for the Updated Guidelines on Indications for Metabolic and Bariatric Surgery (IFSO/ASMBS)

The 2024 evidence update behind the ASMBS/IFSO indications: a systematic report on 13 criteria — BMI thresholds, Asian populations, diabetes, age, adolescents, safety and long-term outcomes — finding the evidence for expanded eligibility strengthened, though several questions rest on observational data.

2024 Evidence Update · International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) and ASMBS

📘 GuidelineCh 11 · Bariatric & Metabolic Surgery⏳ Pending verification

NICE NG246 (England and Wales-facing national guidance)

NICE guideline NG246 on overweight and obesity: specialist multidisciplinary assessment first, bariatric surgery considered inside the defined NHS pathway after appropriate assessment and prior weight-management approaches, with lower BMI thresholds for several ethnic groups.

NG246 — 2025 (updated 2026) · National Institute for Health and Care Excellence (NICE)